Nav: Home

Geneticist Stephen J. Elledge wins Breakthrough Prize

December 05, 2016

Stephen Elledge, the Gregor Mendel Professor of Genetics and of Medicine at Brigham and Women's Hospital and Harvard Medical School, has been named a 2017 recipient of the Breakthrough Prize, which recognizes paradigm-shifting discoveries in the life sciences, physics and mathematics.

Elledge is being honored for his wide-ranging contributions across multiple fields in biology. His work has elucidated critical mechanisms in cell division, cell aging, cancer growth, and protein breakdown and recycling.

The Breakthrough Prize--said to be the largest in the world for science--includes a $3 million award for each recipient and will be celebrated during a televised gala at the NASA Ames Research Center in Silicon Valley and broadcast live on the National Geographic channel on Sunday, Dec. 4, at 10 p.m. E.T.

Get more HMS news here

"This magnificent award is a fitting recognition and acknowledgement of Stephen's outstanding ingenuity, tenacity and vision," said Elizabeth G. Nabel, president of Brigham and Women's Health Care. "We are extremely fortunate to count him among our colleagues here at Brigham and Women's, and congratulate him and this year's other prize winners on their remarkable achievements."

One of Elledge's most pivotal discoveries is unraveling the process by which cells sense DNA damage and initiate self-repair, a critical fail-safe mechanism that safeguards both individual cells and the integrity and health of the entire organism. DNA, which forms the basis of life, fends off constant damage from various sources, including normal metabolic byproducts, environmental toxins, sunlight and normal aging. Such assaults can alter DNA's chemical structure, leaving behind changes, or mutations, in the cell's genetic code. If left unrepaired, these alterations can disrupt key biological processes, leading to serious diseases, including cancer.

A cell's failure to sense the presence of aberrations in its DNA can spark cancerous mutations and malignant cell proliferation.

Elledge's work revealed that a "watchdog" protein-enzyme pair sniff out damaged DNA and send a message to the cell's internal repair machinery to fix the problem. If and when the cell fails to mend its broken DNA, it issues a command to self-destroy. This process, known as cell suicide, or apoptosis, is the body's way of stemming the proliferation of abnormal cells and preventing cancer. Elledge's discoveries explained how and why this mechanism sometimes fails.

Cancer development is an astoundingly complex process. It is the end result of a series of failures in the cell's ability to detect, repair and halt DNA damage.

Unraveling the intricacies of cell behavior in response to DNA stress has been one of the most vexing challenges in genetics, oncology and, indeed, modern medicine. It is also one that holds great therapeutic hope for cancer. Elledge's discoveries explain one of the key steps in this process, and in doing so it sheds light on one of the long-standing mysteries in cancer genomics: Why and how cells sometimes fail to sense the presence of DNA malfunction.

"Stephen's work toward elucidating the way cells sense DNA damage and initiate self-repair is breathtaking in its scope and elegance," said Barbara McNeil, acting dean of the Harvard Medical School. "His passion for discovery, his curiosity and creativity embody the spirit of Harvard Medical School and the noblest traditions in scientific thought and inquiry. This award is a testament to that."

Elledge made his initial observations about DNA damage in yeast while working as a postdoctoral student at Stanford University in the late 1980s. He noticed that levels of a certain enzyme spiked when yeast DNA was damaged or failed to copy itself properly. Speculating that the same enzymatic "alert" mechanism may be at play in the cells of mammals and humans, Elledge relentlessly pursued that notion for the next 20 years.

Working with collaborators from several other institutions, Elledge went on to devise genetic models to test that concept in mammalian and human cells. He went on to describe, step by step, the signaling pathway that regulates the cell's response to DNA damage stress and, ultimately, to identify the central characters that regulate this elaborate, yet elegant, protective mechanism.

Elledge's scientific pursuits culminated in the discovery in the early 2000s of a pair of protein-kinase complexes that engage in an intricate interplay to detect DNA damage, notify one another of its presence and, ultimately, alert the cell's "central command" to the presence of damaged DNA.

"Steve is not only a primary founder of the DNA damage surveillance and response field, he has been its intellectual leader. He has shown the courage to move where the science demands that he move," said Gary Ruvkun, professor of genetics at Harvard Medical School and Massachusetts General Hospital, a winner of the Breakthrough Prize in Life Sciences in 2015, and a member of the current selection committee for the 2017 prize. "Further, he has consistently promoted novel genetic technologies that have had a profound impact on research by many labs, including his own."

Elledge has applied basic principles of mathematics to design technologies that can analyze massive gene databases to help identify candidate genes that may play a role in cancer and autoimmune disorders.

More recently, harnessing the power of proteomics and computational analysis, Elledge and colleagues designed a new method to track the footprints of every single virus a person has been exposed to in a lifetime. That knowledge could help illuminate new understanding of the long-term consequences of past viral encounters and elucidate the role that viruses may play in the development of disorders ranging from cancer to autoimmune diseases to neurodegenerative conditions.

"I'm truly honored to receive the Breakthrough Prize," Elledge said. "It is deeply gratifying to see the profound impact that basic research can have not only in promoting scientific knowledge but also in improving human health."

Elledge plans to apply a significant portion of the funds he receives through the Breakthrough Prize toward philanthropic causes, which will include efforts to promote secondary and higher education with an emphasis on science.

Elledge is a Howard Hughes Medical Institute investigator and member of the Institute of Medicine and the National Academy of Sciences. He is the recipient of numerous awards, including the 2015 Albert Lasker Basic Medical Research Award, the National Academy of Sciences Award in Molecular Biology, the Genetics Society of America Medal, the Paul Marks Prize for Cancer Research and the Dickson Prize in Medicine, among others.

Now in its fifth year, the Breakthrough Prize was founded by Sergey Brin and Anne Wojcicki, Mark Zuckerberg and Priscilla Chan, and Yuri and Julia Milner. Winners are selected by a committee drawn from past Breakthrough Prize laureates.
-end-
Related:

Stephen Elledge: Driven by Questions: VIDEO
https://vimeo.com/138111795

Elledge Lab
http://elledgelab.med.harvard.edu/Breakthrough Prize
https://breakthroughprize.org/

Harvard Medical School

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...